{"id":"metformin-or-sulfonylurea","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Gastrointestinal disturbance (metformin)"},{"rate":"10-20","effect":"Hypoglycemia (sulfonylurea)"},{"rate":"2-3","effect":"Weight gain (sulfonylurea)"},{"rate":"<0.1","effect":"Lactic acidosis (metformin, rare)"}]},"_chembl":{"chemblId":"CHEMBL1431","moleculeType":"Small molecule","molecularWeight":"129.17"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin is a biguanide that reduces gluconeogenesis in the liver and enhances peripheral glucose uptake and utilization, thereby lowering blood glucose without causing hypoglycemia. Sulfonylureas bind to ATP-sensitive potassium channels on beta cells, triggering insulin release to lower blood glucose levels. These are distinct drug classes often used together or separately for type 2 diabetes management.","oneSentence":"Metformin decreases hepatic glucose production and improves insulin sensitivity, while sulfonylureas stimulate pancreatic beta cells to increase insulin secretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:35.687Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05042505","phase":"NA","title":"Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation","status":"COMPLETED","sponsor":"Medanta, The Medicity, India","startDate":"2022-01-01","conditions":"Diabetes Mellitus, Liver Transplant; Complications","enrollment":100},{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT02616666","phase":"PHASE4","title":"A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2016-08-25","conditions":"Type 2 Diabetes Mellitus","enrollment":632},{"nctId":"NCT06528405","phase":"PHASE2","title":"The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-11-21","conditions":"Acute Kidney Injury","enrollment":264},{"nctId":"NCT06778967","phase":"PHASE3","title":"A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-02-13","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":1100},{"nctId":"NCT07241897","phase":"PHASE3","title":"DPP4 Inhibitor Intervention on Post-stroke Cognitive Impairment in Ischemic Stroke Patients With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2025-12-15","conditions":"Ischemic Stroke, Diabete Mellitus","enrollment":312},{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":"Diabetes Mellitus Type 2","enrollment":150},{"nctId":"NCT02695121","phase":"","title":"Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-01-01","conditions":"Breast Cancer, Bladder Cancer","enrollment":2133575},{"nctId":"NCT06716216","phase":"PHASE3","title":"A Study of BGM0504 in Participants with Type 2 Diabetes","status":"RECRUITING","sponsor":"BrightGene Bio-Medical Technology Co., Ltd.","startDate":"2024-11-29","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":537},{"nctId":"NCT02737657","phase":"","title":"An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During Ramadan","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2016-04","conditions":"Diabetes Mellitus, Type 2","enrollment":379},{"nctId":"NCT04017221","phase":"","title":"Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-10-01","conditions":"Diabetes Mellitus, Type 2, Urosepsis, Diabetic Ketoacidosis","enrollment":1249636},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT05284344","phase":"","title":"The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Adelaide","startDate":"2021-01-24","conditions":"Type 2 Diabetes","enrollment":78},{"nctId":"NCT05878535","phase":"PHASE2","title":"METFORMIN FOR ATRIAL FIBRILLATION","status":"UNKNOWN","sponsor":"Arab Contractors Medical Centre","startDate":"2024-06-01","conditions":"Atrial Fibrillation","enrollment":770},{"nctId":"NCT06203275","phase":"PHASE3","title":"The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"aya ramadan ashmawy sarhan","startDate":"2024-01","conditions":"Diabetes Mellitus, Type 2","enrollment":44},{"nctId":"NCT03877406","phase":"PHASE4","title":"Effect of Empagliflozin on Body Composition and Ketones","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2018-08-01","conditions":"Diabetes Mellitus, Fat; Intolerance, Pancreas","enrollment":200},{"nctId":"NCT05688332","phase":"PHASE3","title":"Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM Patients","status":"UNKNOWN","sponsor":"University of Zambia","startDate":"2023-08","conditions":"Diabetes Mellitus Type 2 Without Complication","enrollment":118},{"nctId":"NCT01267448","phase":"PHASE4","title":"Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia","status":"COMPLETED","sponsor":"Cook County Health","startDate":"2014-09-09","conditions":"Diabetes Mellitus Type 2, Hyperglycemia","enrollment":100},{"nctId":"NCT03871621","phase":"PHASE4","title":"Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2019-04-01","conditions":"Type 2 Diabetes Mellitus","enrollment":76},{"nctId":"NCT04093752","phase":"PHASE3","title":"A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-12-09","conditions":"Type 2 Diabetes","enrollment":917},{"nctId":"NCT03076112","phase":"PHASE3","title":"Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2017-04-25","conditions":"Type 2 Diabetes Mellitus","enrollment":170},{"nctId":"NCT01131182","phase":"PHASE4","title":"Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-13","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":1147},{"nctId":"NCT02272556","phase":"NA","title":"Investigating the Role of the Polyol Pathway in the Central Nervous System","status":"COMPLETED","sponsor":"Yale University","startDate":"2015-02","conditions":"Hyperglycemia","enrollment":138},{"nctId":"NCT05360147","phase":"PHASE3","title":"Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Third Military Medical University","startDate":"2021-01-20","conditions":"Type 2 Diabetes Mellitus","enrollment":30},{"nctId":"NCT02836704","phase":"PHASE4","title":"Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-09-09","conditions":"Diabetes Mellitus, Type 2","enrollment":892},{"nctId":"NCT03761134","phase":"PHASE3","title":"Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea","status":"TERMINATED","sponsor":"Sanofi","startDate":"2018-11-30","conditions":"Type 2 Diabetes Mellitus","enrollment":377},{"nctId":"NCT04283318","phase":"NA","title":"Prolonged Fasting on Glucose Metabolism and Hormonal Regulation in Healthy, Obese and Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2018-06-13","conditions":"Healthy, Obesity, Type 2 Diabetes Mellitus","enrollment":80},{"nctId":"NCT03770728","phase":"PHASE3","title":"Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-08-01","conditions":"Type 2 Diabetes Mellitus","enrollment":312},{"nctId":"NCT05055219","phase":"","title":"Conventional and Metabolomic Predictors of Prediabetes & Insulin Resistance","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2015-06","conditions":"PreDiabetes, Obesity, Childhood","enrollment":772},{"nctId":"NCT02922179","phase":"","title":"Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics","status":"COMPLETED","sponsor":"Biologics & Biosimilars Collective Intelligence Consortium","startDate":"2011-01-01","conditions":"Diabetes","enrollment":103951},{"nctId":"NCT04859452","phase":"PHASE1","title":"A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-05-26","conditions":"Healthy Subjects","enrollment":56},{"nctId":"NCT04146155","phase":"PHASE4","title":"Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-01","conditions":"Type 2 Diabetes, Peripheral Vascular Disorder Due to Diabetes Mellitus","enrollment":200},{"nctId":"NCT02686177","phase":"PHASE4","title":"Effect of GLP-1 on Angiogenesis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-05-18","conditions":"Type 2 Diabetes","enrollment":50},{"nctId":"NCT03066830","phase":"PHASE3","title":"Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2017-02-24","conditions":"Type 2 Diabetes Mellitus","enrollment":507},{"nctId":"NCT04013581","phase":"PHASE4","title":"Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2019-08-05","conditions":"Type 2 Diabetes Mellitus","enrollment":121},{"nctId":"NCT03049228","phase":"","title":"In and ex Vivo Mitochondrial Function of the Heart","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2017-03-21","conditions":"Diabetes Mellitus, Type 2, Diabetic Cardiomyopathies","enrollment":38},{"nctId":"NCT02726490","phase":"EARLY_PHASE1","title":"Glyburide vs Glucovance in the Treatment of GDM","status":"TERMINATED","sponsor":"Texas Tech University Health Sciences Center, El Paso","startDate":"2016-07","conditions":"Gestational Diabetes","enrollment":7},{"nctId":"NCT01033773","phase":"NA","title":"Stop Emergency Room Visits for Hyperglycemia Project - District of Columbia (DC)","status":"COMPLETED","sponsor":"Medstar Health Research Institute","startDate":"2007-09","conditions":"Type 2 Diabetes Mellitus","enrollment":86},{"nctId":"NCT03655535","phase":"PHASE2","title":"Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes","status":"COMPLETED","sponsor":"Boston Therapeutics","startDate":"2018-09-19","conditions":"Type2 Diabetes Mellitus","enrollment":66},{"nctId":"NCT02730377","phase":"PHASE4","title":"Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-03-28","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1991},{"nctId":"NCT03893422","phase":"NA","title":"Placebo-Controlled Clinical Nutrition Study of the Safety and Metabolic Effects of Two Medical Foods in Type 2 Diabetes","status":"COMPLETED","sponsor":"Pendulum Therapeutics","startDate":"2017-10-22","conditions":"Type 2 Diabetes Mellitus","enrollment":76},{"nctId":"NCT02043054","phase":"PHASE3","title":"Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Disease","enrollment":90},{"nctId":"NCT02694263","phase":"PHASE4","title":"Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2016-07","conditions":"Diabetes Mellitus, Type 2","enrollment":25},{"nctId":"NCT02292290","phase":"PHASE4","title":"Trial for People With Established Type 2 Diabetes During Ramadan","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2011-04","conditions":"Type 2 Diabetes","enrollment":99},{"nctId":"NCT03850886","phase":"PHASE2","title":"Nicotinamide in Non-Alcoholic Fatty Liver Disease Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2019-01-15","conditions":"Non Alcoholic Fatty Liver Disease","enrollment":61},{"nctId":"NCT02805283","phase":"","title":"Dapagliflozin Patient Satisfaction Survey","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-22","conditions":"Diabetes Mellitus, Type 2","enrollment":653},{"nctId":"NCT01648582","phase":"PHASE3","title":"A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07","conditions":"Type 2 Diabetes Mellitus","enrollment":774},{"nctId":"NCT02686476","phase":"NA","title":"Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Medanta, The Medicity, India","startDate":"2016-03","conditions":"Non Alcoholic Fatty Liver Disease","enrollment":100},{"nctId":"NCT02613897","phase":"NA","title":"ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2016-01","conditions":"Diabetes Mellitus, Type 2","enrollment":56},{"nctId":"NCT03467945","phase":"PHASE1","title":"Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2018-02-16","conditions":"Healthy","enrollment":40},{"nctId":"NCT02128932","phase":"PHASE3","title":"Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-08-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1089},{"nctId":"NCT02471404","phase":"PHASE4","title":"Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09-21","conditions":"Type 2 Diabetes Mellitus, Inadequate Glycaemic Control","enrollment":939},{"nctId":"NCT03421119","phase":"PHASE3","title":"Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes","status":"UNKNOWN","sponsor":"Cinnagen","startDate":"2019-06-20","conditions":"Diabetes Mellitus, Type 2","enrollment":300},{"nctId":"NCT03050619","phase":"","title":"Characteristics of Empagliflozin Initiators","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-09-10","conditions":"Type 2 Diabetes","enrollment":31908},{"nctId":"NCT02551874","phase":"PHASE3","title":"A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-10-20","conditions":"Type 2 Diabetes Mellitus","enrollment":650},{"nctId":"NCT02532855","phase":"PHASE3","title":"A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-20","conditions":"Type 2 Diabetes Mellitus","enrollment":614},{"nctId":"NCT01697592","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":585},{"nctId":"NCT01709305","phase":"PHASE4","title":"A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-11-08","conditions":"Type 2 Diabetes Mellitus","enrollment":5570},{"nctId":"NCT01590771","phase":"PHASE3","title":"A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-09","conditions":"Type 2 Diabetes Mellitus","enrollment":498},{"nctId":"NCT01215331","phase":"PHASE3","title":"Gestational Diabetes: Insulin or Oral Hypoglycemic Agents?","status":"COMPLETED","sponsor":"Université de Sherbrooke","startDate":"2010-08","conditions":"Gestational Diabetes Mellitus","enrollment":73},{"nctId":"NCT00279045","phase":"PHASE3","title":"Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-01-03","conditions":"Diabetes Mellitus, Type 2","enrollment":4426},{"nctId":"NCT03249506","phase":"","title":"Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-05-12","conditions":"Diabetes Mellitus, Type 2","enrollment":25358},{"nctId":"NCT01618162","phase":"PHASE3","title":"The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-08-29","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":435},{"nctId":"NCT02786823","phase":"PHASE2, PHASE3","title":"Effect of Folic Acid and Vitamin B12 Supplementation in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2017-05-01","conditions":"Diabetes Mellitus, Type 2","enrollment":80},{"nctId":"NCT03239119","phase":"PHASE3","title":"The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2017-11-30","conditions":"Type2 Diabetes Mellitus","enrollment":456},{"nctId":"NCT01340768","phase":"PHASE3","title":"Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-22","conditions":"Type 2 Diabetes Mellitus","enrollment":870},{"nctId":"NCT01076075","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-03","conditions":"Type 2 Diabetes Mellitus","enrollment":427},{"nctId":"NCT01357135","phase":"","title":"An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-07-15","conditions":"Type 2 Diabetes Mellitus","enrollment":3453},{"nctId":"NCT00885352","phase":"PHASE3","title":"Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-15","conditions":"Type 2 Diabetes Mellitus","enrollment":313},{"nctId":"NCT00350779","phase":"PHASE3","title":"Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06-12","conditions":"Type 2 Diabetes Mellitus","enrollment":262},{"nctId":"NCT01798706","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Type 2 Diabetes","enrollment":350},{"nctId":"NCT00379769","phase":"PHASE3","title":"RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-04","conditions":"Diabetes Mellitus, Type 2","enrollment":4447},{"nctId":"NCT00789191","phase":"PHASE3","title":"Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":222},{"nctId":"NCT00518882","phase":"PHASE3","title":"Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-08","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":467},{"nctId":"NCT00968812","phase":"PHASE3","title":"CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2009-09","conditions":"Diabetes Mellitus, Type 2","enrollment":1452},{"nctId":"NCT01511172","phase":"PHASE2","title":"Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-08","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":145},{"nctId":"NCT02269098","phase":"NA","title":"The Synergy to Control Emergency Department Hyperglycemia Program for Type 2 Diabetes","status":"COMPLETED","sponsor":"Medstar Health Research Institute","startDate":"2012-02","conditions":"Diabetes Mellitus, Type 2, Medication Adherence, HYPERGLYCEMIA","enrollment":101},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":1417914},{"nctId":"NCT00909597","phase":"PHASE3","title":"A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-05","conditions":"Diabetes Mellitus Type 2","enrollment":756},{"nctId":"NCT01691989","phase":"PHASE3","title":"A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-12","conditions":"Diabetes Mellitus Type 2","enrollment":197},{"nctId":"NCT01169779","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-07","conditions":"Type 2 Diabetes Mellitus","enrollment":391},{"nctId":"NCT01472432","phase":"PHASE4","title":"DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2011-05","conditions":"Chronic Foot Ulcers","enrollment":106},{"nctId":"NCT01944618","phase":"","title":"forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2013-10","conditions":"Type 2 Diabetes","enrollment":5000},{"nctId":"NCT02282423","phase":"NA","title":"PGC-1 & Muscle Mitochondrial Dysfunction in Diabetes","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2014-05","conditions":"Diabetes, Obesity","enrollment":26},{"nctId":"NCT02420392","phase":"NA","title":"Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2015-02","conditions":"Diabetes Mellitus, Type 2","enrollment":30},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Type 2 Diabetes Mellitus","enrollment":1499650},{"nctId":"NCT02475499","phase":"","title":"Incretin-based Drugs and Pancreatic Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":886172},{"nctId":"NCT00486187","phase":"NA","title":"Effects of ROSIglitazone on Inflammatory Markers and Adipokines in Diabetic Patients Using an Angiotensin Receptor Blocker (TELmisartan) - The ROSITEL Study","status":"COMPLETED","sponsor":"Dr. Milan Gupta","startDate":"2006-04","conditions":"Type 2 Diabetes Mellitus","enrollment":103},{"nctId":"NCT00792935","phase":"PHASE2","title":"A Study to Test MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-0941-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-01","conditions":"Type 2 Diabetes Mellitus","enrollment":143},{"nctId":"NCT02027753","phase":"PHASE4","title":"Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-12","conditions":"Diabetes Mellitus, Type 2","enrollment":109},{"nctId":"NCT00700856","phase":"PHASE4","title":"Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial","status":"UNKNOWN","sponsor":"Italian Society of Diabetology","startDate":"2008-09","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Disease","enrollment":3371},{"nctId":"NCT01278485","phase":"","title":"Evaluation of Low Blood Sugar Events in Participants With Diabetes (MK-0431-402)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-05","conditions":"Type 2 Diabetes Mellitus","enrollment":726},{"nctId":"NCT00106704","phase":"PHASE3","title":"Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Diabetes Mellitus, Type 2","enrollment":441},{"nctId":"NCT00641056","phase":"PHASE3","title":"Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-04","conditions":"Type 2 Diabetes Mellitus","enrollment":467},{"nctId":"NCT00313313","phase":"PHASE3","title":"A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-04","conditions":"Diabetes","enrollment":768},{"nctId":"NCT00960661","phase":"PHASE3","title":"A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-09","conditions":"Type 2 Diabetes Mellitus","enrollment":1036},{"nctId":"NCT01003184","phase":"PHASE3","title":"Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-10","conditions":"Type 2 Diabetes Mellitus","enrollment":222},{"nctId":"NCT00660907","phase":"PHASE3","title":"Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-03","conditions":"Type 2 Diabetes","enrollment":1217},{"nctId":"NCT01918865","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2013-08","conditions":"Type 2 Diabetes Mellitus, Obese","enrollment":92},{"nctId":"NCT00324363","phase":"PHASE3","title":"Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-01","conditions":"Type 2 Diabetes Mellitus","enrollment":466}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":41930,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"metformin or sulfonylurea","genericName":"metformin or sulfonylurea","companyName":"Dr. Milan Gupta","companyId":"dr-milan-gupta","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metformin decreases hepatic glucose production and improves insulin sensitivity, while sulfonylureas stimulate pancreatic beta cells to increase insulin secretion. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}